News from

Research

Reset All Filters
1235 Results
Finding solutions for burnout among nurses of color
Group photo at SHINE Invitational.

The Center for Health Outcomes and Policy Research (CHOPR) at the University of Pennsylvania School of Nursing invited nursing researchers and practitioners from Philadelphia and around the country to its Solutions to Health Inequities & Nurses’ Emotional Exhaustion Invitational.

(Image: Kelvin Amenyedor/CHOPR)

Finding solutions for burnout among nurses of color

The Center for Health Outcomes and Policy Research at the School of Nursing brought together nurses and researchers for the Solutions to Health Inequities & Nurses’ Emotional Exhaustion Invitational.
Romance and race
Illustration of a couple walking in a city in the snow.

Image: Adobe Stock/grandfailure

Romance and race

Sociology Ph.D. candidate Olivia Hu is studying how people choose romantic partners across race lines, and how those relationships affect their understandings of social difference.

Susan Ahlborn

New chip opens door to AI computing at light speed
Lit-up lights on a computer chip.

Image: iStock/yucelyilmaz

New chip opens door to AI computing at light speed

A new silicon-photonic (SiPh) chip design from the lab of Nader Engheta, alongside Firooz Aflatouni, uses light waves, the fastest possible means of communication, rather than electricity, to perform mathematical computations.

From Penn Engineering Today

The YouTube algorithm isn’t radicalizing people
A person pressing play on a YouTube video on a smartphone.

Image: Danykur for Adobe Stock

The YouTube algorithm isn’t radicalizing people

A new study from Annenberg School for Communication’s Computational Social Science Lab finds that the YouTube recommendation system is less influential on users’ political views than is commonly believed.

From Annenberg School for Communication

‘Switchable’ bispecific antibodies pave way for safer cancer treatment
Artist's depiction of tumor microenvironment

Bispecific T cell engagers are emerging as a powerful class of immunotherapy to treat cancer but are sometimes hindered by unwanted outcomes, such as on-target, off-tumor toxicity; cytokine release syndrome; and neurotoxicity. Now, researchers Penn researchers have developed a novel “switchable” bispecific T cell engager that mitigates these negative effects by co-opting a drug already approved by the FDA.

(Image: iStock / CIPhotos)

‘Switchable’ bispecific antibodies pave way for safer cancer treatment

Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates negative outcomes of immunotherapy.